P/E at 36.09 vs Industry's 37.19: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Slight Discount to Industry Average

The P/E ratio of 36.09 for Sun Pharmaceutical Industries Ltd suggests the stock is trading at a modest discount of approximately 3% relative to its sector peers. This contrasts with many large-cap pharmaceutical companies that often command significant premiums due to their scale and product portfolios. The industry P/E of 37.19 reflects a sector with generally elevated valuations, driven by growth expectations and innovation pipelines. The near-parity in valuation indicates that the market is pricing in steady earnings growth without excessive optimism or pessimism. This valuation context is crucial for investors analysing whether the stock’s price fairly reflects its fundamentals or if there is room for re-rating — is this valuation discount signalling a buying opportunity or a cautionary flag?

Performance Across Timeframes: Divergent Momentum

Examining Sun Pharmaceutical Industries Ltd’s returns over various periods reveals a mixed performance profile. Over the past year, the stock has appreciated by 20.48%, significantly outperforming the Sensex’s negative 3.70% return. This strong annual performance is complemented by an impressive three-year return of 71.12% and a five-year return of 147.61%, both well ahead of the Sensex’s respective 18.65% and 37.41%. However, the 10-year return of 152.80% trails the Sensex’s 177.58%, indicating some relative underperformance over the longer term.

In contrast, the short-term trend is less encouraging. The stock declined by 3.34% over the last month, while the Sensex gained 0.46%. The three-month return of 3.59% is positive but only slightly ahead of the Sensex’s 1.65%. The one-week gain of 0.54% also outperforms the Sensex’s 0.54% loss, and the one-day gain of 0.56% is marginally better than the Sensex’s 0.24%. This divergence between strong medium-term gains and recent short-term weakness raises questions about the sustainability of momentum — is this a temporary pause or a sign of deeper challenges?

Moving Average Configuration: Mixed Technical Signals

The technical picture for Sun Pharmaceutical Industries Ltd is characterised by a nuanced moving average (MA) configuration. The stock price currently sits above its 5-day, 100-day, and 200-day moving averages, signalling short-term strength and long-term support. However, it remains below the 20-day and 50-day moving averages, which often serve as indicators of intermediate-term momentum. This pattern suggests a recent bounce within a broader consolidation or correction phase rather than a clear breakout or breakdown.

The fact that the stock has gained after two consecutive days of decline, coupled with its position relative to these key MAs, indicates a potential recovery attempt. Yet, the inability to surpass the 20-day and 50-day averages may imply resistance and caution among traders. This mixed MA configuration is a classic sign of a stock in transition — is this a genuine recovery or a dead-cat bounce?

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a varied set of results recently, with 34 stocks having declared their quarterly results. Of these, 14 reported positive outcomes, 15 were flat, and 5 delivered negative results. This distribution reflects a sector grappling with both growth opportunities and headwinds such as regulatory scrutiny, pricing pressures, and supply chain challenges.

Within this context, Sun Pharmaceutical Industries Ltd’s performance stands out for its relative resilience and consistent medium-term gains. The stock’s ability to outperform the Sensex over one, three, and five years despite sector volatility highlights its underlying strength. However, the recent short-term softness aligns with the broader sector’s mixed signals, underscoring the importance of monitoring ongoing developments closely — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Rating Reassessment: Previously Rated Hold

MarketsMOJO had previously assigned a Hold rating to Sun Pharmaceutical Industries Ltd, reflecting a cautious stance amid valuation and performance considerations. The rating was updated on 25 Aug 2026, coinciding with a Mojo Score of 74.0, which indicates a favourable assessment of the company’s fundamentals and technical outlook. This reassessment suggests a shift in the analytical view, taking into account the stock’s recent price action, valuation metrics, and sector dynamics.

Given the stock’s mixed short-term momentum but strong medium-term returns and reasonable valuation, the updated rating reflects a balanced perspective. The data-driven approach behind this reassessment emphasises the importance of integrating multiple factors rather than relying on any single metric — what is the current rating for this large-cap stock?

Conclusion: A Data-Driven View of Sun Pharmaceutical Industries Ltd

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock with a valuation close to its industry peers, strong medium-term performance, but recent short-term volatility and mixed technical signals. The P/E ratio slightly below the sector average suggests the market is pricing in steady earnings without exuberance. The stock’s outperformance over one, three, and five years contrasts with its recent monthly decline, highlighting a tension between momentum timeframes.

The moving average configuration further emphasises this transitional phase, with the stock above some key averages but below others, indicating a tentative recovery rather than a confirmed uptrend. Sector results are mixed, reflecting broader industry challenges and opportunities. The updated rating from previously Hold to a more favourable assessment aligns with these nuanced data points, underscoring the importance of a multi-dimensional analysis.

Investors analysing Sun Pharmaceutical Industries Ltd should consider how these valuation, performance, and technical factors interact — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today